 | Up a level |
2022
Borchmann, Peter, Vandenberghe, Peter, Urbano-Ispizua, Alvaro, Haioun, Corinne, Lemonnier, Francois, Griskevicius, Laimonas, Maury, Sebastien, Holtkamp, Silke, Friedrichs, Birte, Zadoyan, Gregor, Hanssens, Linda, Overstijns, Toon, Assenmacher, Mario, Bethke, Ulf, Buerger, Iris, Reer, Olaf, Jaeger, Ulrich and Kersten, Marie Jose (2022). Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation- DALY 2-EU Trial. Blood, 140. S. 12784 - 12786. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Holzer, Tatjana, Biedermann, Stefanie, Herfort, Inga, Friedrichs, Birte, Holtkamp, Silke, Hanssens, Linda, Assenmacher, Mario, Bethke, Ulf, Schneider, Dina, Miltenyi, Stefan, Overstijns, Toon, Schmid, Christoph, Ayuk, Francis A., Scheid, Christoph, Juehling, Anja, Holtick, Udo, Goedel, Philipp, Borchmann, Peter and Buerger, Iris (2022). Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 140. S. 4581 - 4584. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020